New insights into drug development for pediatric solid tumors: what preclinical data justify clinical trials in pediatric cancer?

Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program

(2013) Richard B. Lock et al.   PEDIATRIC BLOOD & CANCER

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

(2013) E. Anders Kolb et al.   PEDIATRIC BLOOD & CANCER

Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical Response

(2012) H. Wong et al.   CLINICAL CANCER RESEARCH

Raise standards for preclinical cancer research

(2012) C. Glenn Begley et al.   NATURE

Drug development and clinical trials—the path to an approved cancer drug

(2012) Eric H. Rubin et al.   Nature Reviews Clinical Oncology

An Integrated Chemical Biology Approach Identifies Specific Vulnerability of Ewing's Sarcoma to Combined Inhibition of Aurora Kinases A and B

(2011) G. E. Winter et al.   MOLECULAR CANCER THERAPEUTICS

High drug attrition rates—where are we going wrong?

(2011) Lisa Hutchinson et al.   Nature Reviews Clinical Oncology

Believe it or not: how much can we rely on published data on potential drug targets?

(2011) Florian Prinz et al.   NATURE REVIEWS DRUG DISCOVERY

Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program

(2010) Peter J. Houghton et al.   PEDIATRIC BLOOD & CANCER

Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: A report from the Children's Oncology Group

(2008) Steven G. DuBois et al.   PEDIATRIC BLOOD & CANCER